BLA 761184 · Pfizer Ireland Pharmaceuticals
Ngenla
Somatrogon-Ghla · Injection
NovelOrphanCDER novel approval, Jun 27, 2023: To treat growth failure due to inadequate secretion of endogenous growth hormone
Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jun 27, 2023
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
5
4 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat growth failure due to inadequate secretion of endogenous growth hormone
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Somatrogon" as an intervention, any sponsor and status, largest first.
- Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.Pivotal-lookingRecruiting
Rabin Medical CenterAcademic, hospital or other
NCT07226089 · 254 participants (planned) · Start Feb 1, 2026 · Primary completion Dec 2027
Drug: Somatrogon; Genotropin · For: ISS; SGA
Sites: Los Angeles, California; Centennial, Colorado; Jacksonville, Florida · 32 sites in all
- Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenPivotal-lookingCompleted
OPKO Health, Inc.Industry
NCT02968004 · 224 participants · Start Dec 2016 · Primary completion Aug 2019
Drug: MOD-4023; Somatropin · For: Pediatric Growth Hormone Deficiency
Sites: Orange, California; Aurora, Colorado; Centennial, Colorado · 81 sites in all
- Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHDPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT03831880 · 87 participants · Start Feb 7, 2019 · Primary completion Aug 28, 2020
Drug: Genotropin; somatrogon · For: Growth Hormone Deficiency
Sites: Sacramento, California; Aurora, Colorado; Centennial, Colorado · 32 sites in all
OPKO Health, Inc.Industry
NCT03810664 · 49 participants · Start Jan 18, 2019 · Primary completion Apr 19, 2019
Drug: Somatrogon · For: Healthy Male Volunteers
Sites: Miami, Florida
- Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone DeficiencyPivotal-lookingCompleted
OPKO Health, Inc.Industry
NCT03874013 · 44 participants · Start Dec 7, 2017 · Primary completion Mar 6, 2020
Drug: MOD-4023; Genotropin · For: Growth Hormone Deficiency
Sites: Nagakute, Japan; Sakura, Japan; Kitakyushu, Japan · 46 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study.
Deal CL, Steelman J, Vlachopapadopoulou E, et al. · J Clin Endocrinol Metab 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis.
de Fries Jensen L, Antavalis V, Odgaard-Jensen J, et al. · Adv Ther 2024 · Comparative Study, Systematic Review
- Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis.
Mameli C, Orso M, Calcaterra V, et al. · Pharmacol Res 2023 · Meta-Analysis, Systematic Review
- Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study.
Gomez R, Lamoureux R, Turner-Bowker DM, et al. · Front Endocrinol (Lausanne) 2023 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study.
Horikawa R, Tanaka T, Hasegawa Y, et al. · Endocr J 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- A Randomized, Cross-Over Study Investigating the Comparability of Somatrogon-ghla in 2 Different Drug Product Presentations.
Manners A, Korth-Bradley J, Wajnrajch MP · Clin Pharmacol Drug Dev 2024 · Randomized Controlled Trial, Comparative Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.